STILLWATER, Okla., Dec. 10, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company) today announced a significant acceleration of the commercialization timeline for its Round Top heavy rare earth deposit in Texas. The Company now plans to begin commercial production in late 2028, two years earlier than previously anticipated. Round Top is the United States’ richest known deposit of heavy rare earth elements, gallium, and beryllium, and is a cornerstone of USAR’s integrated mine-to-magnet value chain. That value chain also includes a 310,000 sq ft. magnet manufacturing facility in Stillwater, Oklahoma, which is expected to be the largest metal-and-alloy-making and strip-casting capability outside of China, and a processing and separation laboratory in Wheat Ridge, Colorado. “We’re challenging ourselves...

TransUnion also projects delinquency expectations for other major credit products during the next year CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today released its 2026 Consumer Credit Forecast, projecting credit card balances to grow 2.3% year over year (YoY)—the smallest annual increase since 2013, excluding 2020 when pandemic relief programs caused a decline. This moderation reflects consumers navigating persistent economic uncertainty as lenders maintain disciplined underwriting standards. Credit card balances are expected to reach $1.18 trillion by the end of 2026, up from $1.16 trillion in 2025. This increase contrasts sharply with the double-digit growth of 2022 and 2023, but reflects the more modest pace of growth seen in more recent years. Lenders are cautiously expanding credit access for riskier...

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3 Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease1 ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment4-7 Data will be featured in an oral presentation at the 2025 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 10 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people...

Kraken Robotics Inc. announces the successful demonstration of its KATFISH Unmanned Surface Vessel Launch and Recovery System (USV-LARS) from TKMS ATLAS UK’s (ATLAS UK) 11-meter ARCIMS USV. The systems offer a comprehensive autonomous survey package for maritime security missions including mine countermeasure operations and critical underwater infrastructure inspection. Together, ARCIMS and KATFISH USV-LARS provide the industry’s first air-deployable, 300-meter depth rated autonomous towed SAS survey system.ST. JOHN’S, Newfoundland and Labrador, Dec. 10, 2025 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces the successful demonstration of its KATFISH Unmanned Surface Vessel Launch and Recovery System (USV-LARS) from TKMS ATLAS UK’s (ATLAS UK) 11-meter...

How Decades of Innovation Are Converging for Commercial Spider Silk Success DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB)(“the Company”, “Kraig”, “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering a defining phase in its corporate and scientific evolution. What began as a bold idea by Kim Thompson, Kraig’s founder and CEO, more than a decade ago, is now maturing into a viable business model blending genetic engineering, biotechnology, and commercial textile manufacturing. Kraig Labs’ journey, from acquiring key patent rights abandoned by a failed predecessor to developing proprietary gene-insertion...

U.S. Losartan market totals $245M annually with 71M prescriptions  COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. BlinkRx holistically orchestrates and automates patient...

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — CHAR Technologies Ltd. (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to announce that the Ontario government has awarded a $2.25 million non repayable reimbursement grant through the Forest Biomass Program for 50% of eligible project costs to accelerate the Thorold Renewable Energy Facility’s commercialization of biocarbon pellets. The biocarbon pellets are a made-in-Ontario renewable reductant and fuel designed as a drop-in replacement for fossil carbon in steelmaking and other heavy industrial applications. This investment supports CHAR Tech’s work to optimize biocarbon pellet production at the Thorold Renewable Energy Facility, improving durability, density, and handling characteristics required for industrial use and long-distance transport....

CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the pricing of its previously announced underwritten public offering of 11,851,853 shares of its common stock at a public offering price of $13.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,111,193 shares of common stock at a public offering price of $13.499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price of each pre-funded warrant. The gross proceeds to Fulcrum from the offering, before deducting underwriting...

Performance dividend of Cdn$0.05 per Share Declared1Total dividends declared in 2025 surge to Cdn$0.18 per ShareAmerigo’s Capital Return Strategy Fully Deployed in 2025 including 3.97 million shares retiredVANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce that on December 9, 2025, Amerigo’s Board of Directors declared a performance dividend in the amount of Cdn$0.05 per share, payable on January 15, 2026, to shareholders of record as of December 17, 20251. Amerigo designates the entire amount of this taxable dividend to be an “eligible dividend” for purposes of the Income Tax Act (Canada), as amended from time to time. “We are very pleased to declare this performance dividend. A performance dividend underscores...